Pharmaceutical Executive
February 01, 2011
Issue PDF
0
0
The Promise Of Translational Medicine
February 01, 2011
Features
0
0
Novartis' Gilenya is a step forward in treating Multiple Sclerosis. But generating increased compliance is another story
February 01, 2011
Features
0
0
If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshhot of what's ahead for Big Pharma in the country
February 01, 2011
Columns
0
0
Adapting training techniques is necessary to thrive in the fact-changing dynamic of a physician's office
February 01, 2011
Features
0
0
With Francis Collins now calling the shots at NIH, will be be able to deliver on the innovations behind the genome?
February 01, 2011
Columns
0
0
Increased efficiency and lower operating costs for both CROs and vendors can be achieved by eliminating activities
February 01, 2011
Columns
0
0
To manage through a resource-constrained environment, it is essential to get the most out of procurement planning
February 01, 2011
Columns
0
0
The Three Cs could be taxing on FDA resources as the new Congress brings stiffer oversight and leadership revisions to the agency
February 01, 2011
0
0
All this uncertainty at the back end of drug development is a drain on future therapeutic progress against disease. It's a job killer, too.
February 01, 2011
Columns
0
0
With the impact of the sales rep in decline, it's time to beef up training for other pharma functions to fill the gap in a competitive marketplace